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Background
Two main structural classes of cyclic nucleotide receptors
exist in mammalian cells. The first class contains a con-
served cyclic nucleotide binding (CNB) domain, found in
the regulatory regions of PKG and PKA in cyclic nucle-
otide regulated ion channels and in Epac. The second class
contains a GAF domain that can bind cyclic nucleotides
but is structurally unrelated to CNB domains. GAF
domains are present in some phosphodiesterases (PDEs)
allosterically regulated by cyclic nucleotides. In addition,
cGMP and cAMP are bound and hydrolysed by PDEs at
their catalytic site.
Materials and methods
The important feature of this work was to measure 12 of
the most commonly used cyclic nucleotide analogues on
protein kinase A I and II (PKA I and II), protein kinase G
Iα, Iβ and II (PKG Iα, Iβ and II), and the guanine nucle-
otide exchange factor Epac I. The study is extended to
eight cyclic nucleotide hydrolysing phosphodiesterases
(PDE IA, IB, IC, II, IV, V, VI and X), thereby introducing
microcalorimetry to overcome radioactive labeling of the
tested analogs and allowing analysis of the kinetic param-
eters Km, Ki and Vmax [1].
Results and discussion
We successfully used isothermal titration microcalorime-
try (ITC) for analysing the kinetic parameters of eight
PDEs by various cAMP- and cGMP-analogs. The measured
data reflect very well the reported literature and the tech-
nique offers significant advantages over traditional micro-
biological methods. The measuring of both, kcat and Km,
provide additional insight into protein active sites by
determining competitive, non-competitive and linear-
mixed inhibition of the PDEs by the cyclic nucleotides.
To our surprise, some accepted hydrolysis-stable analogs
became degraded by the newer phosphodiesterases or
show high inhibitory effects. As an example, we show side
effects of an Epac specific activator on platelet signalling
pathways.
The defined specificity profiles of the tested cyclic nucle-
otides are presented in clearly arranged tables and will
help to interpret in vivo data in the light of the cyclic nucle-
otide receptor proteins present in a given cell.
An extended overview of the data will be accessible to the
scientific community at: http://www.cyclic-nucle
otides.net after publication.
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